Hiramatsu Masayuki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10275994/publications.pdf

Version: 2024-02-01

23 papers	530 citations	687363 13 h-index	752698 20 g-index
24 all docs	24 docs citations	24 times ranked	633 citing authors

#	Article	IF	Citations
1	Effects of galantamine on social interaction impairments in cholecystokinin receptor-2 overexpression mice. Journal of Pharmacological Sciences, 2022, 148, 364-368.	2.5	0
2	Preventive Effect of Betaine Against Cognitive Impairments in Amyloid Î² Peptide-Injected Mice Through Sirtuin1 in Hippocampus. Neurochemical Research, 2022, 47, 2333-2344.	3.3	8
3	Preventive Effects of Continuous Betaine Intake on Cognitive Impairment and Aberrant Gene Expression in Hippocampus of 3xTg Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 79, 639-652.	2.6	9
4	Reelin Supplementation Into the Hippocampus Rescues Abnormal Behavior in a Mouse Model of Neurodevelopmental Disorders. Frontiers in Cellular Neuroscience, 2020, 14, 285.	3.7	24
5	Galantamine improves enhanced impulsivity, impairments of attention and long-term potentiation induced by prenatal nicotine exposure to mice. Biochemical Pharmacology, 2020, 180, 114139.	4.4	5
6	Paternal valproic acid exposure in mice triggers behavioral alterations in offspring. Neurotoxicology and Teratology, 2019, 76, 106837.	2.4	15
7	Involvement of GAT2/BGT-1 in the preventive effects of betaine on cognitive impairment and brain oxidative stress in amyloid Î² peptide-injected mice. European Journal of Pharmacology, 2019, 842, 57-63.	3.5	23
8	Effect of AceK (acesulfame potassium) on brain function under dietary restriction in mice. Physiology and Behavior, 2018, 188, 291-297.	2.1	22
9	Atypical antipsychotic-induced Hdac2 transcription via NF-Î³B leads to synaptic and cognitive unfavourable effects. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-2.	0.0	0
10	Comparison of twice a day and three times a day meropenem administration in elderly patients in a Japanese community hospital. Nagoya Journal of Medical Science, 2018, 80, 391-400.	0.3	1
11	Prenatal nicotine exposure decreases the release of dopamine in the medial frontal cortex and induces atomoxetine-responsive neurobehavioral deficits in mice. Psychopharmacology, 2017, 234, 1853-1869.	3.1	42
12	Betaine attenuates memory impairment after water-immersion restraint stress and is regulated by the GABAergic neuronal system in the hippocampus. European Journal of Pharmacology, 2017, 796, 122-130.	3.5	28
13	PT565. Prenatal nicotine exposure impairs adolescent mouse hippocampal function. International Journal of Neuropsychopharmacology, 2016, 19, 8-8.	2.1	0
14	Prenatal Nicotine Exposure Impairs the Proliferation of Neuronal Progenitors, Leading to Fewer Glutamatergic Neurons in the Medial Prefrontal Cortex. Neuropsychopharmacology, 2016, 41, 578-589.	5.4	38
15	Cilostazol prevents amyloid Î² peptide_{25â€35}â€induced memory impairment and oxidative stress in mice. British Journal of Pharmacology, 2010, 161, 1899-1912.	5.4	85
16	Longâ€lasting antinociceptive effects of a novel dynorphin analogue, Tyrâ€<scp>D</scp>â€Alaâ€Pheâ€Leuâ€Arg Ïˆ(CH₂NH) Argâ€NH₂, in mice. British Journal of Pharmacology, 2001, 132, 1948-1956.	5.4	22
17	Des-tyrosine1 dynorphin A-(2â€“13) improves carbon monoxide-induced impairment of learning and memory in mice. Brain Research, 2000, 859, 303-310.	2.2	14
18	Improvement by low doses of nociceptin on scopolamine-induced impairment of learning and/or memory. European Journal of Pharmacology, 2000, 395, 149-156.	3.5	39

#	Article	IF	Citations
19	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. British Journal of Pharmacology, 1999, 127, 655-660.	5.4	45
20	Different modulation of cholinergic neuronal systems by dynorphin A (1â€“13) in carbon monoxide-exposed mice. Biochemical Pharmacology, 1999, 57, 1321-1329.	4.4	7
21	Effects of nocistatin on nociceptin-induced impairment of learning and memory in mice. European Journal of Pharmacology, 1999, 367, 151-155.	3.5	71
22	Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous Î¹-opioid receptor agonist. British Journal of Pharmacology, 1998, 123, 920-926.	5.4	28
23	U-50,488H, a selective kappa opoid receptor agonist, ameliorates memory impairments induced by muscarinic autoreceptor agonist, carbachol in mice. Neuroscience Letters, 1997, 236, 45-48.	2.1	4